Pink October 2026 and the move towards more precise cancer care

Precision oncology is moving toward treatments and monitoring tailored to tumour biology, creating selective growth opportunities across biopharma, medical technology, and life-science tools.

• Breast-cancer survival has improved substantially, while molecular tests for hormone receptors and HER2 now help classify tumours and select targeted treatments.
• Antibody-drug conjugates can deliver toxic payloads more directly to HER2-positive cancer cells, and liquid biopsies can detect emerging ESR1 mutations that affect hormone-treatment choices.
• In metastatic pancreatic cancer, a recently approved RAS-blocking treatment nearly doubled median overall survival versus chemotherapy in previously treated patients; radiotheranostics are also using PSMA imaging and targeted radiation in prostate cancer.
• In August 2026, Merck and Moderna reported that their personalised mRNA vaccine combined with pembrolizumab improved recurrence-free and distant metastasis-free survival over pembrolizumab alone in a phase III melanoma trial, although the therapy is not yet approved.
• Candriam sees biopharma valuations around the middle of their cycle, medical-technology valuations below historical averages, and earnings recovery in life-science tools and services beginning in the second quarter of 2026.

Takeaway: Investors should assess oncology companies through both clinical evidence and commercial potential, favouring businesses where scientific advances can produce patient benefits and long-term growth without paying excessive valuations.